Cytosorbents Corp

CTSONASDAQ · USD
4.87USD+4.52 (-9.32%)
312

Cytosorbents Corp (CTSO) Implied Volatility Current

CTSO's 30 day implied volatility is 11,588.48%, with an IV Rank of 100.00%. This is a high IV Rank versus the past year, meaning Cytosorbents Corp options are relatively expensive and currently favor sellers. CTSO's 30 day historical volatility sits at 99.87%, which means implied volatility is running 11,488.61 points above historical volatility, as of Nov 13, 2026.

Read more

Tracking CTSO implied volatility helps you spot when Cytosorbents Corp options are historically cheap or expensive, and where the best trades are hiding. When CTSO IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor CTSO implied volatility current levels in real time and filter for high probability trades.

Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking CTSO IV rank helps you see whether CTSO's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy.

Implied Volatility

IV Rank
100.00%IV Rank
High

IV is highly elevated. Premiums are expensive, strongly favoring sellers.

Implied Volatility (30d)11588.48%

IV Rank100.00%

Historical Volatility (30d)99.87%

IV Minus HV+11,488.61%

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →